Lenvatinib Mesilate
Tier A — Act nowLenvatinib Mesilate · all drugs expiring in 2028 →
Targets：VEGFR1, KIT, VEGFR3, FGFR4, FGFR1, FGFR3, FGFR2, VEGFR2, PDGFR-α, RET
Brand：Lenvima, Kisplyx, Lenvima/Kisplyx
Indications (approved)：Renal cell carcinoma, Endometrial cancer, Hepatocellular carcinoma, Thyroid cancer
Regional status
Synthetic routes & intermediates3 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LENT-001 | 20925-27-3Available | 4-amino-2-chlorobenzonitrile |
| LENT-002 | 7251-09-4Available | 4-amino-2-methoxybenzonitrile |
| LENT-003 | 15568-86-2Available | 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione |
| LENT-004 | 417721-14-3Available | 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)amino)-2-methoxybenzonitrile |
| LENT-005 | 417721-15-4Available | 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carbonitrile |
| LENT-006 | 417721-34-7Available | 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid |
| LENT-007 | 417721-35-8Available | 4-chloro-7-methoxyquinoline-6-carbonyl chloride |
| LENT-008 | 417721-36-9Available | 4-chloro-7-methoxyquinoline-6-carboxamide |
| LENT-009 | 17609-80-2Available | 4-amino-3-chlorophenol |
| LENT-010 | 417722-93-1Available | 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide |
| LENT-011 | 1885-14-9Available | phenyl carbonochloridate |
| LENT-012 | 417722-95-3Available | phenyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate |
| LENT-013 | 86483-52-5Available | cyclopropanamine |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENT-008 | 417721-36-9Available | 4-chloro-7-methoxyquinoline-6-carboxamide |
| LENT-009 | 17609-80-2Available | 4-amino-3-chlorophenol |
| LENT-013 | 86483-52-5Available | cyclopropanamine |
| LENT-016 | 201811-58-7Available | tert-butyl (2-chloro-4-hydroxyphenyl)carbamate |
| LENT-017 | 1808104-64-4Available | tert-butyl (4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)carbamate |
| LENT-018 | 1808104-65-5Available | 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide hydrochloride |
| Code | CAS No. | Intermediate |
|---|---|---|
| LENT-008 | 417721-36-9Available | 4-chloro-7-methoxyquinoline-6-carboxamide |
| LENT-009 | 17609-80-2Available | 4-amino-3-chlorophenol |
| LENT-011 | 1885-14-9Available | phenyl carbonochloridate |
| LENT-013 | 86483-52-5Available | cyclopropanamine |
| LENT-014 | 796848-80-1Available | phenyl (2-chloro-4-hydroxyphenyl)carbamate |
| LENT-015 | 796848-79-8Available | 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropylurea |
Frequently asked questions
What are the approved indications of Lenvatinib Mesilate?
Approved indications include: Renal cell carcinoma, Endometrial cancer, Hepatocellular carcinoma, Thyroid cancer.
When does the Lenvatinib Mesilate patent expire?
Based on public sources, the Lenvatinib Mesilate patent expires in 2028.
How many synthesis routes are recorded for Lenvatinib Mesilate?
3 synthesis routes are recorded; the shortest is 4 steps with 7.78 kg total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Lenvatinib Mesilate intermediates?
18 intermediate CAS of Lenvatinib Mesilate are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Lenvatinib Mesilate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29